EU Deregulates Gene-Edited Crops as Biotech Leader Urges Trust Rebuilding
The EU relaxed rules for gene-edited crops on 28 July 2026, while industry leader Jeremy M. Levin called for ten commitments to rebuild public trust in biotechnology.
This article was drafted with AI assistance from multiple sources and was reviewed and approved by a human editor before publication.
The European Union passed new laws on 28 July 2026 that relax regulations for gene-edited crops, departing from the 20-year-old directives that governed genetically modified organisms. The move marks a significant policy shift for the bloc, which had maintained one of the world's strictest stances on agricultural biotechnology.
The following day, Jeremy M. Levin, chairman of Ovid Therapeutics, published a comment in Nature Biotechnology calling on the industry to take concrete steps to restore public confidence. The comment, adapted from his book 'Biotech in the Balance: Saving a Strategic Industry in an Age of Distrust' (Rodin Books, 2026), proposes ten commitments for biotechnology companies.
Levin argues that the sector must address growing public distrust amid pressures on the institutions that underpin scientific leadership. His ten commitments aim to foster transparency, accountability, and engagement with stakeholders, though the comment does not detail specific measures for each pledge.
The timing of Levin's appeal is notable, coming just one day after the EU's regulatory overhaul. The new rules are expected to accelerate the development and commercialization of gene-edited crops in Europe, potentially boosting agricultural productivity and sustainability. Critics, however, have raised concerns about environmental risks and the need for robust oversight.
Levin's call for trust-building reflects a broader recognition within the biotech industry that public acceptance is critical for long-term success. As gene editing technologies advance, companies will need to navigate not only regulatory frameworks but also societal expectations.